ABBV icon

AbbVie
ABBV

234.00 USD
+1.64
0.71%
At close Updated Nov 17, 4:00 PM EST
Pre-market
After hours
234.86
+0.86
0.37%
1 day
0.71%
5 days
6.85%
1 month
1.93%
3 months
13.28%
6 months
26%
Year to date
30.41%
1 year
40.73%
5 years
135.86%
10 years
287.55%
 

About: AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.

Employees: 55,000

Healthcare Drug Manufacturers - General
0
Funds holding %
of 7,366 funds
Explore Fund Trends
0
Analysts bullish %
of 12 analysts
See Analyst Outlook
0
Positive news %
of 64 articles
Check Journalist POV
Price charts implemented using Lightweight Charts™